GlassScriptPhysician profile
Ashley Lopez
NPI 1578208419
$2,419.27
in general payments reported to CMS, 2019-2025
20 companies · $2,227 in 2025
The $2,227 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $29.54 · 2024: $163 · 2025: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142 · Education: $85.00 · Travel and Lodging: $14.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.10 |
| Education | $85.00 |
| Travel and Lodging | $14.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.00 | 2025 | |
| Ucb, INC. | $247.32 | 2025 | Nayzilam, Fintepla |
| Medtronic, INC. | $220.08 | 2025 | Percept PC Brainsense |
| Amneal Pharmaceuticals LLC | $209.50 | 2025 | Crexont |
| Merz Pharmaceuticals, LLC | $189.50 | 2025 | Xeomin |
| Emd Serono, INC. | $153.46 | 2025 | |
| Genzyme Corporation | $147.46 | 2025 | |
| Argenx US, INC. | $144.26 | 2025 | Vyvgart, Vyvgart Hytrulo |
| E.R. Squibb & Sons, L.L.C. | $121.87 | 2025 | Zeposia |
| Acadia Pharmaceuticals INC | $109.98 | 2025 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.27 | 2025 | Rejoyn |
| Amgen INC. | $57.53 | 2024-2025 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $52.94 | 2025 | Rexulti |
| Biogen, INC. | $44.49 | 2025 | Skyclarys |
| Alexion Pharmaceuticals, INC. | $39.52 | 2025 | Ultomiris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $36.81 | 2025 | |
| Neurelis, INC. | $30.23 | 2025 | Valtoco |
| Penumbra, INC. | $27.82 | 2025 | Smart Coil |
| Jazz Pharmaceuticals INC. | $23.33 | 2025 | |
| Octapharma USA, INC. | $19.06 | 2025 | Fibryga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.